Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

Recruiting

Phase 1

Phase 2

Glofitamab, Ibrutinib, ObinutuzumabGlofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

Sponsor:

OHSU Knight Cancer Institute

Code:

NCT06357676

Conditions

Mantle Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Marrow Biopsy

Computed Tomography

Echocardiography

FDG-Positron Emission Tomography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-13. This information was provided to ClinicalTrials.gov by OHSU Knight Cancer Institute on 2026-01-30.